The landscape of prostate cancer treatment has undergone a significant transformation in recent years, particularly regarding the management of patients who exhibit signs of recurrence after initial primary treatment. For patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) who face biochemical recurrence (BCR) at high risk for metastasis, the standard of care has long been a subject of intense clinical investigation.
A pivotal breakthrough in this field is the Phase III EMBARK trial (NCT02319837). In a recent scholarly podcast featured in the journal Future Oncology, two of the study’s lead investigators—Dr. Neal Shore, Medical Director of the Carolina Urologic Research Center, and Dr. Henry Woo, an academic urological surgeon based in Sydney—delved into the trial’s landmark findings, safety profiles, and the profound implications for modern clinical practice.
The Challenge of Biochemical Recurrence
Biochemical recurrence is defined by a rise in prostate-specific antigen (PSA) levels following radical prostatectomy or radiation therapy, signaling that the disease may still be present despite initial curative efforts. For patients at high risk of metastasis—characterized by rapid PSA doubling times—the clinical goal is to delay the progression to metastatic disease, a stage that fundamentally alters the prognosis and treatment trajectory of the patient.
Historically, the standard treatment for these patients has been androgen deprivation therapy (ADT), often administered via agents like leuprolide. However, the EMBARK trial sought to determine whether the addition of enzalutamide—a potent androgen receptor pathway inhibitor (ARPI)—or the use of enzalutamide as a monotherapy, could provide superior clinical outcomes compared to the traditional standard of care.
Chronology of the EMBARK Study
The EMBARK trial was a massive, international, randomized Phase III undertaking that spanned 17 countries and 244 clinical sites. Enrollment for the study took place between January 2015 and August 2018, with a total of 1,068 patients participating.
The trial was designed with three distinct arms, utilizing a 1:1:1 randomization ratio:
- Combination Therapy: Enzalutamide plus leuprolide.
- Monotherapy: Enzalutamide alone.
- Standard of Care: Placebo plus leuprolide (the control arm).
A unique feature of the trial design was the "treatment suspension" protocol. To evaluate the efficacy of intermittent therapy, treatment was suspended at week 37 if the patient achieved a PSA level of <0.2 ng/mL at week 36. Treatment was then reinitiated if the PSA reached specific thresholds (5.0 ng/mL for patients without previous radical prostatectomy, or 2.0 ng/mL for those who had undergone surgery). This design aimed to provide patients with "off-therapy" periods while maintaining strict control to prevent the development of metastatic disease.
Supporting Data: Efficacy and Metastasis-Free Survival
The primary endpoint of the EMBARK trial was metastasis-free survival (MFS), a metric widely recognized as a robust surrogate for overall survival in localized prostate cancer. After a median follow-up of 60.7 months, the results were definitive.
The combination of enzalutamide and leuprolide significantly outperformed the control group. Patients in the combination arm experienced an 87% 5-year MFS rate, compared to 71% in the leuprolide-only group. Statistically, this represented a 58% lower risk of metastasis or death, with a hazard ratio of 0.42.
Equally compelling were the results for the enzalutamide monotherapy arm, which served as a key secondary endpoint. The 5-year MFS for the monotherapy group was 80%, representing a 37% lower risk of metastasis or death compared to leuprolide alone (hazard ratio of 0.63). These findings were highly statistically significant, providing a strong foundation for the use of ARPI monotherapy—a treatment strategy that had not previously been thoroughly vetted in large-scale randomized controlled trials.
Secondary outcomes, including time to PSA progression and time to the initiation of new antineoplastic therapy, also favored the enzalutamide-based regimens. While overall survival (OS) data remain immature, the trends are positive, and researchers continue to monitor the patient cohort for long-term survival benefits.
Safety Profiles and Patient-Reported Outcomes (PROs)
A major concern in oncology trials is the impact of treatment intensification on a patient’s quality of life (QOL). According to Dr. Woo, the EMBARK trial revealed no new safety signals. The adverse event (AE) profile was consistent with the known side effects of enzalutamide and ADT.
More than 97% of patients across all arms reported at least one adverse event of any grade. However, the nature of these events varied by treatment arm. While hot flashes and fatigue were the most common AEs in the combination and control groups, the monotherapy group reported higher instances of gynecomastia, nipple pain, and breast tenderness. Conversely, patients on monotherapy reported fewer hot flashes, offering a potential advantage for those for whom thermoregulatory issues are a primary concern.
Crucially, patient-reported outcomes indicated that health-related quality of life was preserved across all treatment groups. Using metrics such as the Functional Assessment of Cancer Therapy – Prostate (FACT-P) and the Brief Pain Inventory – Short Form (BPI-SF), researchers found no clinically meaningful differences in functional status or pain levels between the treatment groups. This suggests that the clinical benefits of delaying metastasis are achieved without compromising the patient’s day-to-day well-being.
Implications for Clinical Practice
The findings of the EMBARK trial have already begun to reshape international clinical guidelines. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have approved enzalutamide for use in this setting.
However, Dr. Shore and Dr. Woo emphasize that the "one-size-fits-all" approach is no longer the gold standard. Instead, the trial highlights the importance of shared decision-making. Physicians now have the option to offer either combination therapy or monotherapy, depending on the patient’s clinical presentation, personal preferences, and tolerance for specific side effects.
Critical Considerations for Clinicians:
- Treatment Intensification: Following the precedents set by the SPARTAN (apalutamide), PROSPER (enzalutamide), and ARAMIS (darolutamide) trials, treatment intensification is now the standard of care for patients with high-risk nmCRPC.
- Imaging Technology: While EMBARK relied on conventional imaging, the rise of PSMA PET technology is changing how clinicians detect recurrence. Further research is needed to determine how PSMA PET findings should be integrated into treatment decisions for the high-risk BCR population.
- Limitations and Future Directions: Dr. Shore acknowledged that the current study has limitations, including the underrepresentation of non-White patients and the ongoing need for more mature overall survival data. Furthermore, while the monotherapy group was open-label, it provided vital evidence that is now guiding clinical practice. Future investigations will likely focus on the long-term consequences of prolonged enzalutamide exposure and the development of better tools to measure sexual function and other specific quality-of-life domains.
Conclusion: A New Era of Precision
The EMBARK trial stands as a landmark study that provides high-level evidence for managing high-risk biochemically recurrent prostate cancer. By demonstrating that enzalutamide, both as a combination agent and a monotherapy, significantly delays metastasis while preserving quality of life, the study has provided clinicians with powerful new tools to extend the lives of their patients.
As Dr. Shore noted in his closing remarks, the excitement generated by such trials is the driving force behind clinical innovation. While there is still more to learn—particularly regarding long-term outcomes and the integration of novel imaging—the EMBARK results represent a major victory in the ongoing fight against prostate cancer progression. For patients and providers alike, this data offers a clearer, more effective path forward in an increasingly complex therapeutic landscape.
About the Author
